Development Portfolio by Therapeutic Area

Listed below are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 6, 2025. Whether any of the listed compounds ultimately becomes a marketed product depends on the results of clinical studies, the competitive landscape of the potential product's market, reimbursement decisions by payers and the manufacturing processes necessary to produce the potential product on a commercial scale, among other factors. There can be no assurance that we will seek regulatory approval of any of these compounds or that, if such approval is sought, it will be obtained. There is also no assurance that a compound which gets approved will be commercially successful. At this stage of development, we cannot determine all intellectual property issues or all the patent protection that may, or may not, be available for these investigational compounds.

Hematology

Phase I

Investigational Compounds

BCL6 LDD

– Lymphoma

CD33-GSPT1 ADC

– Acute Myeloid Leukemia

CK1α Degrader

– Hematologic Malignancies

Dual Targeting BCMAxG-PRC5D CAR T

– Relapsed/Refractory Multiple Myeloma

HbF Activating CELMoD

– Sickle Cell Disease

Phase II

Additional Indications

BREYANZI

– Relapsed/Refractory Marginal Zone Lymphoma

***REBLOZYL*✦**

– A-Thalassemia

Investigational Compounds

arlo-cel (GPRC5D CAR T)

– Relapsed/Refractory Multiple Myeloma

golcadomide

– Relapsed/Refractory Follicular Lymphoma

Phase III

Additional Indications

***REBLOZYL*✦**

– 1L NTD Myelodysplastic Syndrome Associated Anemia

– 1L TD Myelofibrosis Associated Anemia

Investigational Compounds

arlo-cel (GPRC5D CAR T)

– 2-4L Multiple Myeloma

golcadomide

– High Risk 1L Large B-cell Lymphoma

iberdomide

– 2L+ Multiple Myeloma

– Post-Autologous Stem Cell Therapy Maintenance Newly Diagnosed Multiple Myeloma

mezigdomide

– 2L+ Multiple Myeloma Kd

– 2L+ Multiple Myeloma Vd

Approved Indications

ABECMA

– 3L+ Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

BREYANZI

– 2L+ Large B-cell Lymphoma

– 3L+ CLL/SLL

– 3L+ FL

– 3L+ MCL

EMPLICITI + POMALYST/IMNOVID

– Relapsed/Refractory Multiple Myeloma

EMPLICITI + REVLIMID

– Relapsed/Refractory Multiple Myeloma

IDHIFA

– Relapsed/Refractory Acute Myeloid Leukemia

INREBIC

– Myelofibrosis

ONUREG

– Post-Induction Acute Myeloid Leukemia Continued Treatment/Maintenance

***OPDIVO*✦**

– Relapsed/Refractory Classical Hodgkin Lymphoma

POMALYST/IMNOVID

– Relapsed/Refractory Multiple Myeloma

– AIDS related Kaposi Sarcoma

– HIV-negative Kaposi Sarcoma

***REBLOZYL*✦**

– Transfusion-Dependent Beta-Thalassemia Associated Anemia

– MDS RS or MDS/MPN-RS-T Adult Patients and Previously Treated with ESA – MDS Associated Anemia in ESA naïve patients who may require RBC Transfusion

REVLIMID

– Mantle Cell Lymphoma

– MDS

– Multiple Myeloma

– Follicular Lymphoma

– Marginal Zone Lymphoma

SPRYCEL

– 1L CML

– Acute Lymphoblastic Leukemia with Resistance or Intolerance to Prior Therapy

– Refractory CML

Note: Above pipeline excludes clinical collaborations

✦ Development Partnerships: *AUGTYRO:* Zai Lab; BMS-986495: Prothena; *COBENFY*: Zai Lab; iza-bren (EGFRxHER3 ADC): SystImmune; *KRAZATI*: Zai Lab; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; *OPDIVO*, *YERVOY*, *OPDUALAG,* nivolumab + relatlimab HD, Anti-CCR8 + nivolumab: Ono; PKCθ Inhibitor: Exscientia; *REBLOZYL*: Merck; rHuPH20: Halozyme

Partner-run study

Oncology

Phase I

Investigational Compounds

Anti-CCR8
– Solid Tumors

BMS-986460
– Prostate Cancer

BMS-986463
– Solid Tumors

BMS-986482
– Solid Tumors

BMS-986484
– Solid Tumors

BMS-986488
– Solid Tumors

BMS-986490
– Solid Tumors

HELIOS CELMoD
– Solid Tumors

iza-bren (EGFRxHER3 ADC)✦
– 1L NSCLC#
– Metastatic NSCLC
– Solid Tumors#

PRMT5 Inhibitor
– Solid Tumors

RYZ101
– Extensive Stage SCLC
– HR+/HER2- Unresectable Metastatic Breast Cancer

RYZ801
– Hepatocellular Carcinoma

SOS1 Inhibitor
– Solid Tumors

Phase II

Additional Indications

KRAZATI✦
– 1L NSCLC PD-L1<50%

Phase III

Additional Indications

KRAZATI✦
– 1L NSCLC PD-L1≥50%
– 2L Colorectal Cancer

OPDIVO✦
– Adjuvant Hepatocellular Carcinoma
– Peri-adjuvant Muscle Invasive Urothelial Carcinoma

OPDIVO✦ + YERVOY✦
– 1L Hepatocellular Carcinoma

OPDUALAG✦
– Adjuvant Stage III/IV Melanoma

Investigational Compounds

AR LDD
– Metastatic Castration-Resistant Prostate Cancer

atigotatug (Anti-Fucosyl GM1) + nivolumab
– 1L Extensive Stage SCLC

nivolumab + relatlimab HD✦
– 1L NSCLC PD-L1≥1%

RYZ101
– 2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors

subcutaneous nivolumab + relatlimab + rHuPH20✦
– 1L Melanoma

Approved Indications

ABRAXANE
– Gastric (Japan Only)
– Locally Advanced or Metastatic NSCLC
– Metastatic Breast Cancer

AUGTYRO✦
– ROS1+ NSCLC
– NTRK-Positive Locally Advanced or Metastatic Solid Tumors

KRAZATI✦
– 2L+ KRASG12C-mutated Advanced NSCLC
– KRASG12C-mutated CRC after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy

OPDIVO✦
– Metastatic Melanoma
– 1L Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
– 1L Metastatic Esophageal
– 1L MIUC cis-eligible
– Adjuvant Melanoma
– Adjuvant Urothelial Carcinoma
– Adjuvant Esophageal/Gastroesophageal
– Neoadjuvant NSCLC
– Perioperative NSCLC
– Previously treated advanced RCC
– Previously treated Gastric cancer (Japan)
– Previously treated Metastatic Head & Neck
– Previously treated Metastatic MSI-High CRC
– Previously treated Metastatic NSCLC
– Previously treated Metastatic Urothelial Cancer
– Previously treated Metastatic Esophageal Cancer

OPDIVO QVANTIG
– Indicated for subcutaneous use in most previously approved adult, solid tumor *Opdivo* indications

OPDIVO✦ + cabozantinib✦
– 1L Advanced RCC

OPDIVO✦ + YERVOY✦
– 1L Metastatic Melanoma
– 1L Mesothelioma
– 1L Metastatic NSCLC
– 1L Advanced RCC
– 1L+ MSI-High CRC
– Previously treated Metastatic MSI-High CRC
– Previously treated HCC
– 1L Esophageal

OPDUALAG
– 1L Melanoma

YERVOY✦
– Adjuvant Melanoma
– Metastatic Melanoma

Immunology

Phase I

Investigational Compounds

BMS-986454
- Autoimmune Disease

CD19 NEX T
- Autoimmune Diseases
- Severe Refractory Systemic Lupus Erythematosus

IL2-CD25
- Autoimmune Disease

PKCθ Inhibitor✦
- Autoimmune Disease

Phase II

Additional Indications

SOTYKTU
- Discoid Lupus Erythematosus

Investigational Compounds

afimetoran
- Systemic Lupus Erythematosus

BMS-986322 (TYK2 Inhibitor)
- Moderate-to-Severe Psoriasis

Phase III

Additional Indications

SOTYKTU
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Sjögren's Syndrome

Investigational Compounds

admilparant (LPA1 Antagonist)
- Idiopathic Pulmonary Fibrosis
- Progressive Pulmonary Fibrosis

obexelimab✦
- IgG4-Related Disease

Approved Indications

ORENCIA
- Moderate-to-Severe JIA Intravenous
- Moderate-to-Severe JIA Subcutaneous
- Psoriatic Arthritis
- Moderate-to-Severe RA Auto injector
- Moderate-to-Severe RA Intravenous
- Moderate-to-Severe RA Subcutaneous
- Prophylaxis of Acute Graft versus Host Disease

SOTYKTU
- Adults with Moderate-to-Severe Plaque Psoriasis

ZEPOSIA
- Relapsing forms of Multiple Sclerosis
- Moderate-to-Severe UC

Cardiovascular

Phase II

Investigational Compounds

MYK-224
- Heart Failure with Preserved Ejection Fraction

Phase III

Additional Indications

CAMZYOS
- Non-Obstructive Hypertrophic Cardiomyopathy

Investigational Compounds

milvexian✦
- Acute Coronary Syndrome#
- Atrial Fibrillation#
- Secondary Stroke Prevention#

Approved Indications

CAMZYOS
- Symptomatic NHYA Class II-III Obstructive Hypertrophic Cardiomyopathy

ELIQUIS
- Stroke Risk Reduction in Non-Valvular Atrial Fibrillation
- Treatment of Venous Thromboembolism and Risk Reduction after Initial Therapy
- Prophylaxis of Deep Vein Thrombosis after Hip or Knee Replacement Surgery

Neuroscience

Phase I

Investigational Compounds

BMS-986495✦
- Neurodegenerative Diseases

CD19 NEX T
- Multiple Sclerosis
- Myasthenia Gravis

eIF2B Activator
- Alzheimer's Disease

TRPC4/5 Inhibitor
- Mood and Anxiety Disorders

Phase II

Investigational Compounds

Anti-MTBR Tau
- Alzheimer's Disease

FAAH/MGLL Dual Inhibitor
- Alzheimer's Disease Agitation
- Multiple Sclerosis Spasticity

Phase III

Additional Indications

COBENFY
- Adjunctive Schizophrenia
- Psychosis in Alzheimer's Disease

Approved Indications

COBENFY
- Adults with Schizophrenia